
Expedeon
Reagents and kits for protein-based research.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | €120m | Acquisition | |
Total Funding | 000k |
EUR | 2017 | 2018 |
---|---|---|
Revenues | 0000 | 0000 |
% growth | - | (86 %) |
EBITDA | 0000 | 0000 |
% EBITDA margin | 20 % | (11 %) |
Profit | 0000 | 0000 |
% profit margin | 100 % | 86 % |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Expedeon operated as a specialized life sciences entity, providing reagents and kits to the protein-based research market. The company was originally founded in 2003 in the United Kingdom and later evolved through a series of corporate changes, including operating as the German public company Sygnis AG, which was renamed Expedeon AG in 2018. The firm's business model was centered on a "Grow, Buy, and Build" strategy, which involved driving organic growth through internal R&D, acquiring complementary companies, and integrating them to expand its technology portfolio and market reach. This strategy successfully expanded its customer base from a primarily academic focus to include industrial clients in the diagnostics and pharmaceutical sectors.
The company's product portfolio was extensive, offering solutions for protein electrophoresis, proteomics, protein purification, Western Blotting, and sample preparation. Key product lines included the InstantBlue protein stain, Lightning-Link® antibody and protein labeling kits, and CaptSure™ immunoassay technology. These products were designed to streamline complex laboratory processes, for instance, the Lightning-Link® kits enabled antibody conjugation in under 30 seconds. The business served life science researchers in both academic institutions and industrial settings, enabling the development of new diagnostics and therapeutics.
A significant milestone occurred in January 2020 when Expedeon AG's proteomics and immunology business was acquired by Abcam plc for a sum of €120 million. This transaction included flagship brands like Lightning-Link® and CaptSure™. Following the divestment, Expedeon AG rebranded to 4basebio AG, shifting its strategic focus towards DNA manufacturing for the gene therapy and gene vaccine markets. The remaining genomics business was subsequently spun off into a new entity, 4basebio SE, listed on the London Stock Exchange, while 4basebio AG continued as an investment-focused company.
Keywords: proteomics, life science reagents, antibody conjugation, protein labeling, immunoassay technology, Western Blotting, protein purification, electrophoresis, genomics, DNA manufacturing, diagnostics development, drug discovery, Lightning-Link, CaptSure, InstantBlue, Abcam, 4basebio, life sciences research, protein analysis, biomarker research
Tech stack
Investments by Expedeon
Edit